Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
PSA Screening for HIM Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2022 · third_quarter · Q3
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Source: Senate LDA
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration; S. 2599/H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action."
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration (S 2599 and HR 4356: "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022.")
United States Innovation and Competition Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities. Policies related to the reauthorization of the Prescription Drug User Fee Act. Policies related to the FDA in S. 1260, "US Innovation and Competition Act," and HR 4521, "America COMPETES Act." Issues related to platform technologies and other FDA-related provisions in S. 3799, "PREVENT Pandemics Act."
United States Innovation and Competition Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - "Build Back Better Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act."
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Food and Drug Amendments of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Food and Drug Amendments of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
United States Innovation and Competition Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
United States Innovation and Competition Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities. Policies related to the reauthorization of the Prescription Drug User Fee Act. Policies related to the FDA in S. 1260, "US Innovation and Competition Act," and HR 4521, "America COMPETES Act." Issues related to platform technologies and other FDA-related provisions in S. 3799, "PREVENT Pandemics Act."
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration (S 2599 and HR 4356: "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022.")
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration; S. 2599/H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action."
PREVENT Pandemics Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
PREVENT Pandemics Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
PREVENT Pandemics Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities. Policies related to the reauthorization of the Prescription Drug User Fee Act. Policies related to the FDA in S. 1260, "US Innovation and Competition Act," and HR 4521, "America COMPETES Act." Issues related to platform technologies and other FDA-related provisions in S. 3799, "PREVENT Pandemics Act."
FDASLA Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
FDASLA Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
A resolution supporting the goals and ideals of World Sickle Cell Awareness Day.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"); S Res 477, expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; HR 6000, "Cures 2.0"; and, Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act," and Senate companion legislation (no specific bill).
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"); S Res 477, expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; HR 6000, "Cures 2.0"; and, Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act," and Senate companion legislation (no specific bill).
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration (S 2599 and HR 4356: "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022.")
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration (S 2599 and HR 4356: "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022.")
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act," and related provisions debated in Senate (no specific bill).
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"); S Res 477, expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; HR 6000, "Cures 2.0"; and, Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act," and Senate companion legislation (no specific bill).
Cures 2.0 Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"); S Res 477, expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; HR 6000, "Cures 2.0"; and, Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act," and Senate companion legislation (no specific bill).
Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"); S Res 477, expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; HR 6000, "Cures 2.0"; and, Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act," and Senate companion legislation (no specific bill).
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration (S 2599 and HR 4356: "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022.")
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration (S 2599 and HR 4356: "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022.")
A resolution expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"); S Res 477, expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; HR 6000, "Cures 2.0"; and, Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act," and Senate companion legislation (no specific bill).
Consolidated Appropriations Act, 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response and extension of health programs (H.R. 133, "Consolidated Appropriations Act, 2021").
Consolidated Appropriations Act, 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response and extension of health programs (H.R. 133, "Consolidated Appropriations Act, 2021").
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act").
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act"); Issues related to Administration actions on pharmaceutical pricing (no specific bills).
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act").
Fairness in Orphan Drug Exclusivity Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act" and HR 4712: "Fairness in Orphan Drug Exclusivity Act.").
Fairness in Orphan Drug Exclusivity Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act" and HR 4712: "Fairness in Orphan Drug Exclusivity Act.").
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act").
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act"); Issues related to Administration actions on pharmaceutical pricing (no specific bills).
Families First Coronavirus Response Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act").
Families First Coronavirus Response Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act"); Issues related to Administration actions on pharmaceutical pricing (no specific bills).
CARES Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act" and HR 4712: "Fairness in Orphan Drug Exclusivity Act.").
CARES Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act"); Issues related to Administration actions on pharmaceutical pricing (no specific bills).
CARES Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act" and HR 4712: "Fairness in Orphan Drug Exclusivity Act.").
CARES Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act").
CARES Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act").
CARES Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act").
Lower Health Care Costs Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act").
Lower Health Care Costs Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act"); Issues related to Administration actions on pharmaceutical pricing (no specific bills).
Lower Health Care Costs Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act").
Prescription Drug Pricing Reduction Act of 2019
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act"); Issues related to Administration actions on pharmaceutical pricing (no specific bills).
Prescription Drug Pricing Reduction Act of 2019
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act").
Prescription Drug Pricing Reduction Act of 2019
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act").
Prescription Drug STAR Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: More Efficient Tools to Realize Information for Consumers Act, and S. 1895: "Lower Health Care Costs Act").
Prescription Drug STAR Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "More Efficient Tools to Realize Information for Consumers Act", and S. 1895: "Lower Health Care Costs Act").
Prescription Drug STAR Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "FAIR Drug Pricing Act," and S. 1895: "Lower Health Care Costs Act").
More Efficient Tools to Realize Information for Consumers Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: More Efficient Tools to Realize Information for Consumers Act, and S. 1895: "Lower Health Care Costs Act").
More Efficient Tools to Realize Information for Consumers Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "More Efficient Tools to Realize Information for Consumers Act", and S. 1895: "Lower Health Care Costs Act").
More Efficient Tools to Realize Information for Consumers Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "FAIR Drug Pricing Act," and S. 1895: "Lower Health Care Costs Act").
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: More Efficient Tools to Realize Information for Consumers Act, and S. 1895: "Lower Health Care Costs Act").
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "More Efficient Tools to Realize Information for Consumers Act", and S. 1895: "Lower Health Care Costs Act").
Lower Health Care Costs Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: More Efficient Tools to Realize Information for Consumers Act, and S. 1895: "Lower Health Care Costs Act").
Lower Health Care Costs Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "More Efficient Tools to Realize Information for Consumers Act", and S. 1895: "Lower Health Care Costs Act").
Lower Health Care Costs Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "FAIR Drug Pricing Act," and S. 1895: "Lower Health Care Costs Act").
Prescription Drug Pricing Reduction Act of 2019
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "More Efficient Tools to Realize Information for Consumers Act", and S. 1895: "Lower Health Care Costs Act").
Prescription Drug Pricing Reduction Act of 2019
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: More Efficient Tools to Realize Information for Consumers Act, and S. 1895: "Lower Health Care Costs Act").
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to the Orphan Drug Tax Credit (no specific bills). Issues related to H.R. 1, The Tax Cuts & Jobs Act, including the Orphan Drug Tax Credit, corporate tax rate, foreign earnings rate, and employee benefits.
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2022 · second_quarter · Q2
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - "Build Back Better Act."
Issues related to funding for the Food and Drug Administration; S. 2599/H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action."
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2022 · first_quarter · Q1
General education about FDA approval policies and NIH research activities. Policies related to the reauthorization of the Prescription Drug User Fee Act. Policies related to the FDA in S. 1260, "US Innovation and Competition Act," and HR 4521, "America COMPETES Act." Issues related to platform technologies and other FDA-related provisions in S. 3799, "PREVENT Pandemics Act."
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act."
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to funding for the Food and Drug Administration (S 2599 and HR 4356: "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022.")
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2021 · fourth_quarter · Q4
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act," and related provisions debated in Senate (no specific bill).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"); S Res 477, expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; HR 6000, "Cures 2.0"; and, Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act," and Senate companion legislation (no specific bill).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to funding for the Food and Drug Administration (S 2599 and HR 4356: "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022.")
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2021 · third_quarter · Q3
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act."
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Issues related to funding for the Food and Drug Administration (S 2599 and HR 4356: "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022.")
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2021 · second_quarter · Q2
Issues related to corporate and international tax policy and research and development tax credits (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2021 · first_quarter · Q1
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to the development and application of gene and cell therapies (no specific bills); Issues related to health care cost and price transparency (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to corporate tax law and international tax policies (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2020 · fourth_quarter · 4A
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response and extension of health programs (H.R. 133, "Consolidated Appropriations Act, 2021").
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2020 · fourth_quarter · Q4
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response and extension of health programs (H.R. 133, "Consolidated Appropriations Act, 2021").
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2020 · third_quarter · Q3
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act" and HR 4712: "Fairness in Orphan Drug Exclusivity Act.").
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act"); Issues related to Administration actions on pharmaceutical pricing (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2020 · second_quarter · Q2
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act" and HR 4712: "Fairness in Orphan Drug Exclusivity Act.").
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act").
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2020 · first_quarter · Q1
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act").
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2019 · fourth_quarter · Q4
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "More Efficient Tools to Realize Information for Consumers Act", and S. 1895: "Lower Health Care Costs Act").
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2019 · third_quarter · Q3
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: More Efficient Tools to Realize Information for Consumers Act, and S. 1895: "Lower Health Care Costs Act").
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2019 · second_quarter · Q2
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "FAIR Drug Pricing Act," and S. 1895: "Lower Health Care Costs Act").
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2019 · first_quarter · Q1
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills). Issues related to health care cost and price transparency (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2018 · fourth_quarter · Q4
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2018 · first_quarter · 1A
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2018 · third_quarter · Q3
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills).
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2018 · second_quarter · Q2
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills).
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2018 · first_quarter · Q1
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2017 · fourth_quarter · Q4
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 3921, the HEALTHY KIDS ACT, and S. 1827, the KIDS Act, to reauthorize the State Children's Health Insurance Program.
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills).
Issues related to the Orphan Drug Tax Credit (no specific bills). Issues related to H.R. 1, The Tax Cuts & Jobs Act, including the Orphan Drug Tax Credit, corporate tax rate, foreign earnings rate, and employee benefits.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2017 · third_quarter · Q3
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 3921, the HEALTHY KIDS ACT, and S. 1827, the KIDS Act, to reauthorize the State Children's Health Insurance Program.
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 1628 - American Health Care Act of 2017, issues related to the repeal of the Affordable Care Act (ACA); H.R. 2430 - FDA Reauthorization Act of 2017, provisions related to extending user-free programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2017 · second_quarter · Q2
Issues related to the Orphan Drug Tax Credit (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid.
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 1628 - American Health Care Act of 2017, issues related to the repeal of the Affordable Care Act (ACA); H.R. 2430, the FDA Reauthorization Act of 2017, provisions related to extending user-free programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2017 · first_quarter · Q1
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 1628 - American Health Care Act of 2017, issues related to the repeal of the Affordable Care Act (ACA); H.R. 1223 - OPEN Act, provisions related to amending the Federal Food, Drug, and Cosmetic Act to authorize extension of exclusivity periods for certain drugs approved for a new indication for a rare disease or condition.
Issues related to rare disease and orphan disease patient access in Medicaid.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2016 · fourth_quarter · Q4
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 5122, "To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models."
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2016 · third_quarter · Q3
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 5122, "To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models."
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2016 · second_quarter · Q2
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016. S. Res. 476, Designating the month of May 2016 as "Cystic Fibrosis Awareness Month."
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 5122, "To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models."
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act").
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit (no specific bills). Issues related to comprehensive corporate tax reform (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE